We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
Read MoreHide Full Article
Ireland-based medical device major Medtronic plc (MDT - Free Report) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.
Last quarter, the company posted earnings of $1.12 per share, surpassing the Zacks Consensus Estimate by a penny. In fact, Medtronic’s earnings have outpaced the Zacks Consensus Estimate in three of the past four quarters, with an average beat of 0.92%. Let’s see how things are shaping up prior to this announcement.
Factors at Play
With Medtronic recording a significant percentage of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener for the company over the last few quarters. Considering this impact, for fiscal 2017, Medtronic anticipates currency headwind to the tune of approximately 20 cents to 22 cents.
Also difficult macroeconomic conditions in certain countries across the world have led to reduction in healthcare budgets and increased pressure on utilization. Management has projected that the company’s revenue growth is likely to remain under pressure in Middle East in the rest of 2017, which will affect the forthcoming quarterly results.
Given the current macro-economic trend, Medtronic had earlier lowered its revenue growth guidance for fiscal 2017. The company currently expects revenue growth for the fiscal to be within the mid-single digit range compared with its original expectation of the upper half of the mid-single digit range. Earlier, during the fiscal second quarter earnings release, the company declared that full-year revenues will be adversely affected by approximately $20–$60 million, including an average of $10–$30 million negative impact in the third quarter. The lowered guidance is all the more disappointing, indicating no chances of improvement down the line.
Notably, there have been multiple developments which should get reflected in Medtronic’s to-be-reported quarter’s results. Under the Cardiac and vascular group, Medtronic received IDE approval from FDA for its IN.PACT Admiral drug-coated balloon. It added new tools to expand its coronary suite and received reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its transcatheter CoreValve Evolut R System. Very recently management also received FDA approval for its FreezorXtra Cryoablation Catheter to treat patients with abnormal heart rhythm. Under the Diabetes Group, the company recently joined forces with Fitbit to create an integrated diabetes care management program. Within the Minimally Invasive Technologies Group, Medtronic received CE Mark for the Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients.
Thus, we expect the company to witness strong share gains from the flow of recent product launches, which should also get reflected in the fiscal third-quarter performance.
In this regard we note that, there has been no change in the estimate revision trend over the last seven days. The same can be observed in the magnitude of the estimate revision trend with earnings estimates remaining at $1.11, over the same time frame.
Earnings Whispers
Our proven model does not conclusively show that Medtronic is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Medtronic has an Earnings ESP of -0.90%. That is because the Most Accurate estimate is pegged at 1.10 whereas the Zacks Consensus Estimate is pegged at $1.11. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Medtronic has a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our proven model shows they have the right combination of elements to post an earnings beat in the upcoming quarter:
Exelixis, Inc. (EXEL - Free Report) has an Earnings ESP of +200.00% and a Zacks Rank #2.
Zynerba Pharmaceuticals, Inc. has an Earnings ESP of +2.74% and a Zacks Rank #2.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
Ireland-based medical device major Medtronic plc (MDT - Free Report) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.
Last quarter, the company posted earnings of $1.12 per share, surpassing the Zacks Consensus Estimate by a penny. In fact, Medtronic’s earnings have outpaced the Zacks Consensus Estimate in three of the past four quarters, with an average beat of 0.92%. Let’s see how things are shaping up prior to this announcement.
Factors at Play
With Medtronic recording a significant percentage of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener for the company over the last few quarters. Considering this impact, for fiscal 2017, Medtronic anticipates currency headwind to the tune of approximately 20 cents to 22 cents.
Medtronic PLC Price and EPS Surprise
Medtronic PLC Price and EPS Surprise | Medtronic PLC Quote
Also difficult macroeconomic conditions in certain countries across the world have led to reduction in healthcare budgets and increased pressure on utilization. Management has projected that the company’s revenue growth is likely to remain under pressure in Middle East in the rest of 2017, which will affect the forthcoming quarterly results.
Given the current macro-economic trend, Medtronic had earlier lowered its revenue growth guidance for fiscal 2017. The company currently expects revenue growth for the fiscal to be within the mid-single digit range compared with its original expectation of the upper half of the mid-single digit range. Earlier, during the fiscal second quarter earnings release, the company declared that full-year revenues will be adversely affected by approximately $20–$60 million, including an average of $10–$30 million negative impact in the third quarter. The lowered guidance is all the more disappointing, indicating no chances of improvement down the line.
Notably, there have been multiple developments which should get reflected in Medtronic’s to-be-reported quarter’s results. Under the Cardiac and vascular group, Medtronic received IDE approval from FDA for its IN.PACT Admiral drug-coated balloon. It added new tools to expand its coronary suite and received reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its transcatheter CoreValve Evolut R System. Very recently management also received FDA approval for its FreezorXtra Cryoablation Catheter to treat patients with abnormal heart rhythm. Under the Diabetes Group, the company recently joined forces with Fitbit to create an integrated diabetes care management program. Within the Minimally Invasive Technologies Group, Medtronic received CE Mark for the Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients.
Thus, we expect the company to witness strong share gains from the flow of recent product launches, which should also get reflected in the fiscal third-quarter performance.
In this regard we note that, there has been no change in the estimate revision trend over the last seven days. The same can be observed in the magnitude of the estimate revision trend with earnings estimates remaining at $1.11, over the same time frame.
Earnings Whispers
Our proven model does not conclusively show that Medtronic is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Medtronic has an Earnings ESP of -0.90%. That is because the Most Accurate estimate is pegged at 1.10 whereas the Zacks Consensus Estimate is pegged at $1.11. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Medtronic has a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our proven model shows they have the right combination of elements to post an earnings beat in the upcoming quarter:
Masimo Corporation (MASI - Free Report) has an Earnings ESP of +3.51% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exelixis, Inc. (EXEL - Free Report) has an Earnings ESP of +200.00% and a Zacks Rank #2.
Zynerba Pharmaceuticals, Inc. has an Earnings ESP of +2.74% and a Zacks Rank #2.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>